Gastroesophageal Reflux Disease (GERD) Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Gastroesophageal Reflux Disease (GERD) Market Overview

Gastroesophageal reflux disease (GERD) is a common gastrointestinal condition that can significantly affect daily comfort, eating habits, sleep, and overall quality of life. Its persistent symptoms may require lifestyle modifications, medications, or medical intervention, depending on disease severity and individual patient needs. The market is influenced by the growing burden of reflux-related symptoms, increasing diagnosis rates, and demand for effective treatment options. Advances in pharmacological therapies, diagnostic approaches, and minimally invasive procedures are supporting market development. The market was valued at USD 5.16 Billion in 2025. Increasing healthcare awareness and improved access to treatment are also contributing to market growth.

Gastroesophageal Reflux Disease (GERD) Market Growth Analysis and Key Influencers

Gastroesophageal Reflux Disease (GERD) Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Gastroesophageal Reflux Disease (GERD) Market Growth Drivers

Expanding Access to Advanced Anti-Reflux Procedures Strengthens the Market Landscape

The growing adoption of advanced anti-reflux procedures is supporting market growth by expanding treatment options for patients with difficult-to-treat disease. For instance, in June 2025, Implantica announced that the National Institute for Health and Care Excellence (NICE) issued positive recommendations for the RefluxStop procedure in National Health Service public hospitals for patients with GERD and ineffective esophageal motility. Implantica noted that up to 40%–50% of the estimated 1 billion people with acid reflux have ineffective esophageal motility. Such recommendations can improve access to specialized interventions and strengthen demand for innovative GERD treatment options.

Gastroesophageal Reflux Disease (GERD) Market Restraints

High Healthcare Costs and Diagnostic Uncertainty May Constrain Market

High healthcare costs and inconsistent diagnostic criteria may limit market expansion by increasing the economic burden of disease management and complicating patient identification. According to Nilanka Wickramasinghe et al., 2025, GERD prevalence estimates range from 5% to 25%, with a systematic-review estimate of 13.98%. The study also reported that the United States spends approximately USD 10 billion annually on GERD diagnosis and treatment. These costs, combined with diagnostic uncertainty, may restrict timely diagnosis, treatment access, and broader market adoption.

Gastroesophageal Reflux Disease (GERD) Market Opportunities

Rising Demand for Long-Term Therapies Creates New Growth Potential in the Market

Increasing demand for effective, long-term GERD therapies is creating expansion potential for innovative treatment approaches. For instance, in November 2025, Implantica reported five-year RefluxStop outcomes showing that 97.9% of patients were free from daily proton pump inhibitor medication at five years, alongside safety data from a 602-patient cohort. The report also highlighted that GERD affected an estimated 17.9% of Japanese adults. Strong clinical evidence and rising disease prevalence can support broader adoption of durable treatment options and expand market growth.

Gastroesophageal Reflux Disease (GERD) Market Trends

Some of the notable trends in the market are next-generation acid suppression and broader treatment innovation.

Increasing Adoption of Potassium-Competitive Acid Blockers Is Likely to Boost the Market Growth

The market is witnessing a shift toward advanced acid-suppression therapies that provide faster and more sustained symptom control. For instance, in June 2026, Onconic Therapeutics filed a New Drug Application in India for Jaqbo (zastaprazan), a potassium-competitive acid blocker, after completing a Phase 3 trial in erosive GERD. This reflects increasing investment in next-generation pharmacological treatments, particularly in high-growth markets such as India. The trend is expected to strengthen market growth.

Gastroesophageal Reflux Disease (GERD) Market Share

Non-Erosive Reflux Disease Is Positioned to Lead GERD Market by Disease Type

The market is segmented by disease type into non-erosive reflux disease (NERD), erosive esophagitis, Barrett's esophagus-associated GERD, and refractory GERD. Among these, non-erosive reflux disease is expected to lead, supported by its substantial patient population and persistent symptom burden. For instance, in January 2026, Sebela Pharmaceuticals submitted a New Drug Application for tegoprazan covering NERD, Erosive Esophagitis healing, and maintenance. The company reported that NERD treatment with tegoprazan improved 24-hour and overnight heartburn and regurgitation. Continued innovation for NERD is expected to reinforce its leading market position.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Gastroesophageal Reflux Disease (GERD) Market Analysis by Region

The regions included in the market are the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these countries, the United States is expected to lead, supported by a large patient population and rapid adoption of innovative therapies. For instance, in July 2024, the U.S. Food and Drug Administration approved VOQUEZNA (vonoprazan) for heartburn associated with non-erosive GERD. Phathom Pharmaceuticals estimated that 45 million U.S. adults have non-erosive GERD, with approximately 15 million receiving prescription treatment annually. Strong demand and treatment innovation are expected to sustain U.S. market leadership.

Leading Players in the Gastroesophageal Reflux Disease (GERD) Market

Gastroesophageal Reflux Disease (GERD) Market Segmentation

Key Questions Answered in the Gastroesophageal Reflux Disease (GERD) Market Report

• What was the gastroesophageal reflux disease (GERD) market value in 2025?
• What is the gastroesophageal reflux disease (GERD) market forecast outlook for 2026-2035?
• What are the major factors aiding the gastroesophageal reflux disease (GERD) market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major gastroesophageal reflux disease (GERD) market trends?
• Which disease type is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which end user is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players involved in the gastroesophageal reflux disease (GERD) market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a structured mixed-methods research approach combining:

• Primary Research: Insights from interviews and consultations with gastroenterologists, gastrointestinal surgeons, healthcare providers, treatment decision-makers, and industry experts across the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India, focusing on disease burden, treatment patterns, unmet needs, and adoption of pharmacological and interventional therapies.
• Secondary Research: Peer-reviewed literature, epidemiological studies, clinical trial records, regulatory information from the FDA, NICE, and other relevant authorities, and company disclosures covering GERD therapies, including RefluxStop, VOQUEZNA, tegoprazan, and potassium-competitive acid blockers.
• Validation: Market estimates are triangulated through top-down and bottom-up approaches and cross-validated against published evidence, regulatory updates, and expert insights.